Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    iCMLf Forum Round tablesJanuary 2018 - Webstreams of the presentations from the iCMLf Forum for Physicians from Emerging Regions 2017 are now available to view. This year's Forum focused on 'Perspectives on the management of CML'. iCMLf experts gave the global perspective followed by local emerging regions perspectives from Russia and Brazil and a discussion with the audience. 
    A new highlight this year was the ‘Meet the expert’ session with small group discussions on the management of TKI’s exclusively for physicians from the emerging regions.

    Topics include:

    1. Perspectives on Molecular Monitoring for CML 
      Associate Professor Susan Branford (Australia) and Dr Elza Lomaia (Russia) 
    2. Perspectives on Treatment Free Remission
      Professor Susanne Saußele (Germany) and Dr Katia Pagnano (Brazil)

    Click on the presentations below to view the webstreams and see the slides.
    (We are very grateful for the support of Brandcast media to produce these web streams) 





    Prof Susan Branford

    Associate Professor
    Susan Branford
    Adelaide, Australia

    Perspectives on Molecular Monitoring for CML:
    A global perspective

    Topics include; molecular monitoring for best patient outcomes, milestone molecular responses in the first 12 months, ELN recommends repeat testing before changing therapy, trend of decline is an important prognostic factor, long-term molecular monitoring is recommended, a rise in a long term optimal responder may indicate non-adherence, frequent monitoring is associated with better adherence on TKI therapy and decreased risk of progression. 





    Dr Elza Lomaia

    Dr Elza Lomaia
    St Petersburg, Russia

    Perspectives on Molecular Monitoring in CML:
    Perspectives from Russia

    Topics include; CML patients outcome by CCyR in Russia, National guidelines for the diagnosis and treatment of CML, the first Russian certified kit for RT-PCR of BCR-ABL, international standardization of Russian labs, challenges with MRD assessment, educational seminars to improve doctors adherence to guidelines.







    Discussion 1


    Q&A Session 1:
    Perspectives on Molecular Monitoring for CML  

    Moderated by Timothy Hughes, Chairman of the iCMLf                                       





    Prof Susanne SaußeleProfessor Susanne Saußele
    Mannheim, Germany

    Perspectives on Treatment Free Remission:
    A global perspective 

    Topics include; cessation of tyrosine kinase inhibitor treatment in CML, STIM trial: molecular recurrence-free survival, summary of imatinib TFR studies and other TFR studies, molecular recurrence-free vs. treatment-free survival, TKI withdrawal syndrome, prognostic indicators of sustained TFR, STOP 2G TKI study results, DADI trial: TFR after discontinuation of dasatinib, what about second stop?.








    Dr Katia PagnanoDr Katia Pagnano
    Campinas, Brazil

    Perspectives on Treatment Free Remission:
    Perspectives from Brazil

    Topics include; outpatients public health system - Brazil procedure, discontinuation trials in Brazil including USP trial: imatinib discontinuation in patients with CML-CP with sustainded MR4log and EDI-PIO: pilot study of imatinb discontinuation in patients with CML with deep molecular response, barriers for TKI discontinuation in Brazil outside clinical trials. 










    Discussion 2


    Q&A Session 2:
    Perspectives on Treatment Free Remission 

     Moderated by Timothy Hughes, Chairman of the iCMLf